Gunnar Folprecht

21.8k total citations · 5 hit papers
198 papers, 10.7k citations indexed

About

Gunnar Folprecht is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Gunnar Folprecht has authored 198 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Oncology, 88 papers in Pulmonary and Respiratory Medicine and 46 papers in Pathology and Forensic Medicine. Recurrent topics in Gunnar Folprecht's work include Colorectal Cancer Treatments and Studies (123 papers), Gastric Cancer Management and Outcomes (47 papers) and Lung Cancer Treatments and Mutations (41 papers). Gunnar Folprecht is often cited by papers focused on Colorectal Cancer Treatments and Studies (123 papers), Gastric Cancer Management and Outcomes (47 papers) and Lung Cancer Treatments and Mutations (41 papers). Gunnar Folprecht collaborates with scholars based in Germany, France and Belgium. Gunnar Folprecht's co-authors include Eric Van Cutsem, Philippe Rougier, Claus-Henning Köhne, Michael Schlichting, J. Załuski, Christopher Stroh, Jae Kyung Roh, Erika Hitre, Sabine Tejpar and G. Bodoky and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Gunnar Folprecht

189 papers receiving 10.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

2009 2.9k citations Eric Van Cutsem, Claus-Henning Köhne et al. profile →
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

2011 1.4k citations Eric Van Cutsem, Claus-Henning Köhne et al. Journal of Clinical Oncology profile →
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

2009 671 citations Gunnar Folprecht, Florian Lordick et al. profile →
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial

2017 414 citations Murielle Mauer, Gunnar Folprecht et al. profile →
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).

2024 37 citations Jens Hoeppner, Thomas Brunner et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Gunnar Folprecht

Since Specialization

Citations

This map shows the geographic impact of Gunnar Folprecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gunnar Folprecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gunnar Folprecht more than expected).

Fields of papers citing papers by Gunnar Folprecht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gunnar Folprecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gunnar Folprecht. The network helps show where Gunnar Folprecht may publish in the future.

Co-authorship network of co-authors of Gunnar Folprecht

This figure shows the co-authorship network connecting the top 25 collaborators of Gunnar Folprecht. A scholar is included among the top collaborators of Gunnar Folprecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gunnar Folprecht. Gunnar Folprecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies. 2024 ·Journal of Clinical Oncology ·Shubham Pant, Joon Oh Park, Wu‐Chou Su, Martin Schüler, (unknown), Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Gunnar Folprecht, Helen Winter, Graziela Zibetti Dal Molin, Hussein Sweiti, (unknown), Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin‐Hsun Feng	1
2	Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). breakdown → 2024 ·Journal of Clinical Oncology ·Jens Hoeppner, Thomas Brunner, Florian Lordick, Claudia Schmoor, Birte Kulemann, Ulf P. Neumann, Gunnar Folprecht, Tobias Keck, Frank Benedix, (unknown), (unknown), Christiane J. Bruns, Johan Friso Lock, Benedikt Reichert, Michael Ghadimi, Kai Wille, Ines Gockel, Jakob R. Izbicki, Stefan Utzolino, Peter Grimminger	37
3	58P Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials 2024 ·Annals of Oncology ·(unknown), Anna Saborowski, Jaewon Hyung, (unknown), Il Hwan Kim, Henning Wege, Kwang Pyo Kim, Gunnar Folprecht, B-Y. Ryoo, (unknown), Jun Cheon, Thorsten Oliver Goetze, Hyewon Ryu, (unknown), Arndt Vogel	0
4	1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial 2023 ·Annals of Oncology ·Shubham Pant, Dirk Arnold, Josep Tabernero, Yohann Loriot, Gunnar Folprecht, Georg Martin Haag, Daniel H. Palmer, Hans Prenen, Jermaine Coward, Iwona Ługowska, (unknown), Andrés Cervantes, Martin Gutierrez, Hussein Sweiti, Constance Hammond, (unknown), Shibu Thomas, Spyros Triantos, (unknown), (unknown)	2
5	P-386 Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer 2023 ·Annals of Oncology ·Harpreet Wasan, Sara Lonardi, Jayesh Desai, Gunnar Folprecht, Claire Gallois, (unknown), Shahid A. Khan, (unknown), Julien Taı̈eb	1
6	O-5 Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG 2023 ·Annals of Oncology ·Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, Sylvie Lorenzen, Olivier Bouché, Peter Thuss‐Patience, Anneli Elme, Markus Moehler, Uberto Fumagalli Romario, Yoon‐Koo Kang, Gunnar Folprecht, Uwe M. Martens, (unknown), Michel Ducreux, M. Díez García, Guillaume Piessen, (unknown), Florian Lordick	3
7	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives 2021 ·Cancer Treatment Reviews ·Gunnar Folprecht, Erika Martinelli, Thibault Mazard, Dominik Paul Modest, Akihito Tsuji, Regina Esser, Chiara Cremolini, Alfredo Falcone	13
8	Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient WithETV6-NTRK3Fusion-Positive Carcinoma Harboring theNTRK3^G623RSolvent-Front Mutation 2021 ·JCO Precision Oncology ·Dorothea Hanf, Christoph Heining, (unknown), (unknown), Sebastian Uhrig, Barbara Hutter, Arne Jahn, Daniela Richter, Daniela E. Aust, Friederike Herbst, Stefan Fröhling, Hanno Glimm, Gunnar Folprecht	4
9	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial 2020 ·European Journal of Cancer ·(unknown), Emmanouil Fokas, Michael Flentje, Rolf Sauer, Torsten Liersch, Ullrich Graeven, Rainer Fietkau, Werner Hohenberger, Dirk Arnold, Ralf‐Dieter Hofheinz, Michael Ghadimi, Philipp Ströbel, Ludger Staib, Gerhard G. Grabenbauer, Gunnar Folprecht, Simon Kirste, Wolfgang Uter, Christine M. Gall, Claus Rödel, Bülent Polat	13
10	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy 2018 ·Clinical Cancer Research ·Claire Gallois, Julien Taı̈eb, Delphine Le Corre, Karine Le Malicot, Josep Tabernero, Claire Mulot, Jean‐François Seitz, Thomas Aparicio, Gunnar Folprecht, Côme Lepage, Enrico Mini, Jean‐Luc Van Laethem, Jean‐François Emile, Pierre Laurent‐Puig	24
11	Immunotherapy of Colon Cancer 2018 ·Oncology Research and Treatment ·Alexander Stein, Gunnar Folprecht	31
12	Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy 2017 ·Annals of Oncology ·Claire Gallois, Julien Taı̈eb, Delphine Le Corre, Karine Le Malicot, Josep Tabernero, Claire Mulot, (unknown), Thomas Aparicio, Gunnar Folprecht, Christian Lepage, Enrico Mini, (unknown), JF Émile, Pierre Laurent‐Puig	7
13	Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) – a retrospective, central evaluation of FIRE-3 2016 ·Annals of Oncology ·Ulf P. Neumann, Timm Denecke, Johann Pratschke, Hauke Lang, Marc H.A. Bemelmans, Thomas Becker, Markus Rentsch, Daniel Seehofer, Christiane J. Bruns, Bernhard Gebauer, Gunnar Folprecht, Sebastian Stintzing, Swantje Held, Volker Heinemann, Dominik Paul Modest	3
14	Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial 2016 ·Annals of Oncology ·Julien Taı̈eb, Karine Le Malicot, (unknown), Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean‐Luc Van Laethem, (unknown), Claire Mulot, Serge Fratté, (unknown), (unknown), J. Thaler, Lone Nørgård Pétersen, (unknown), John Bridgewater, Géraldine Perkins, Côme Lepage, Aziz Zaanan, Pierre Laurent‐Puig	2
15	O-021 Analysis of DNA mismatch repair and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials 2015 ·Annals of Oncology ·Aziz Zaanan, Qian Shi, Julien Taı̈eb, Steven R. Alberts, Thomas C. Smyrk, C. Julié, Ayman Zawadi, Josep Tabernero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean‐Luc Van Laethem, Karine Le Malicot, Daniel J. Sargent, Pierre Laurent‐Puig, Frank A. Sinicrope	1
16	Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy 2011 ·Cancer Research ·Niels Halama, Sara Michel, Matthias Kloor, Inka Zoernig, Axel Benner, Anna Spille, Thora Pommerencke, (unknown), Gunnar Folprecht, Birgit Luber, (unknown), Uwe M. Martens, Philipp Beckhove, Sacha Gnjatic, Peter Schirmacher, Esther Herpel, Juergen Weitz, Niels Grabe, Dirk Jaeger	321
17	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status breakdown → 2011 ·Journal of Clinical Oncology ·Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, I. Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, Ilhan Celik, Philippe Rougier, Fortunato Ciardiello	1441
18	The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri 2008 ·Annals of Oncology ·Eric Van Cutsem, István Láng, G D’Haens, (unknown), J. Załuski, (unknown), Gunnar Folprecht, Sabine Tejpar, Yaroslav Shparyk, M. Schlichting, O. Kisker, Christopher Stroh, P Rougier	11
19	Carcinoma of Unknown Primary – an Orphan Disease? 2008 ·Breast Care ·(unknown), (unknown), Andreas Schneeweiß, Gunnar Folprecht, Kai Neben	17
20	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma 2005 ·Annals of Oncology ·Gunnar Folprecht, Manfred P. Lutz, Patrick Schöffski, Thomas Seufferlein, Arno Nolting, (unknown), C.-H. Köhne	192

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact